Immunology/Inflammation Apoptosis Metabolic Enzyme/Protease Epigenetics PI3K/Akt/mTOR Cell Cycle/DNA Damage JAK/STAT Signaling Stem Cell/Wnt NF-κB Protein Tyrosine Kinase/RTK MAPK/ERK Pathway
Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine ammonium

Cat. No.: HY-113402B

Copy Link Print Information

Gamma-glutamylcysteine ammonium

Name: Gamma-glutamylcysteine ammonium
Brand: MedChemExpress
SKU: HY-113402B
Availability: PreOrder

(Synonyms: γ-Glu-Cys ammonium)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Gamma-glutamylcysteine ammonium (γ-Glu-Cys ammonium) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine ammonium activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine ammonium regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine ammonium is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

For research use only. We do not sell to patients.

Formula: C₈H₁₇N₃O₅S
Molecular Weight:267.30

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (297 KB)

Gamma-glutamylcysteine ammonium Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

All Endogenous Metabolite Isoforms :

All AMPK Isoforms :

All Sirtuin Isoforms :

All STAT Isoforms :

All PI3K Isoforms :

All NF-κB Isoforms :

All JAK Isoforms :

All p38 MAPK Isoforms :

All JNK Isoforms :

All Akt Isoforms :

In Vitro

Gamma-glutamylcysteine ammonium (0-80 μM; 24 h) inhibits M1 polarization of Raw264.7 macrophages by suppressing the JAK1/STAT1/3, AKT, MAPKs and NF-κB signaling pathways, while activating the AMPK/SIRT1 axis^[1].
Gamma-glutamylcysteine ammonium (0-80 μM; 24 h) promotes M2 polarization of Raw264.7 macrophages, and drives their repolarization from M1 to M2 via activation of the IL-4/STAT6 and AMPK/SIRT1 signaling pathways^[1].
Gamma-glutamylcysteine ammonium (20-80 μM; 24 h) induces the polarization of human Jurcat CD4⁺ T lymphocytes toward Th2 by promoting IL-4 secretion^[1].
Gamma-glutamylcysteine ammonium (2 mM; 6 h) activates the Nrf2 signaling pathway via nuclear translocation and upregulates the expression of antioxidant target genes and proteins in primary intestinal epithelial cells (IECs) of chicken embryos^[2].
Gamma-glutamylcysteine ammonium (2 mM; 6 h) inhibits oxidative stress induced by Salmonella typhimurium in primary wild-type chicken embryonic intestinal epithelial cells (IECs) by maintaining Nrf2 activation^[2].
Gamma-glutamylcysteine ammonium (2 mM; 6 h) protects primary intestinal epithelial cells (IECs) from wild-type chicken embryos against intestinal barrier disruption and inflammatory injury induced by Salmonella typhimurium, and this protective effect depends on the Nrf2 signaling pathway^[2].
Gamma-glutamylcysteine ammonium (20-80 μM; administered for 24 h after 24 h of pre-treatment with insulin + PA) dose-dependently activates the IGF-1R/IRS1/PI3K/Akt signaling pathway in insulin-resistant HepG2 cells, primary mouse hepatocytes and C2C12 myotubes induced by Insulin (HY-P701240) + Palmitic acid (HY-N0830) (PA), by increasing the phosphorylation levels of key pathway proteins^[3].
Gamma-glutamylcysteine ammonium (2-4 mM; 2 h pretreatment followed by 12 h cadmium exposure) inhibits the activation of JNK/p38 MAPK and PI3K/Akt signaling pathways in cadmium-treated cells by downregulating the expression of pro-apoptotic markers and normalizing the Bax/Bcl-2 ratio. This consequently suppresses cadmium-induced changes in apoptosis-related proteins, inhibits cadmium-induced cell apoptosis, and prevents cadmium-induced mitochondrial transmembrane potential depolarization in PC12 cells^[4].
Gamma-glutamylcysteine ammonium (2-4 mM; 2 h pretreatment followed by 12 h cadmium exposure) dose-dependently inhibits cadmium-induced oxidative stress in PC12 cells by reducing ROS and lipid peroxidation levels, restoring antioxidant enzyme activity, and maintaining intracellular GSH homeostasis^[4].
Gamma-glutamylcysteine ammonium (0.25-16 mM; 24 h) shows no toxicity to BV-2 cells at concentrations up to 4 mM after 24 h of incubation, while higher concentrations (8, 16 mM) reduce cell viability in a dose-dependent manner^[5].
Gamma-glutamylcysteine ammonium (2-4 mM; 30 min pretreatment, 24 h AβO exposure) dose-dependently inhibits the release of proinflammatory mediators (TNF-α, IL-1β, NO) and the expression of proinflammatory proteins (iNOS, COX-2) induced by AβO in BV-2 cells, suppresses AβO-induced oxidative stress, and restores the antioxidant capacity of cells^[5].
Gamma-glutamylcysteine ammonium (4 mM; 30 min pretreatment, followed by 6-24 h of AβO exposure) inhibits AβO-induced activation of the NF-κB signaling pathway in BV-2 cells, upregulates and maintains the expression of Nurr1 mRNA and protein, and thereby exerts anti-inflammatory effects by suppressing the binding of NF-κB p65 to the iNOS promoter induced by AβO in BV-2 cells^[5].
Gamma-glutamylcysteine ammonium (2-4 mM; 30 min pretreatment, followed by 24 h AβO exposure) dose-dependently inhibits the release of proinflammatory mediators (TNF-α, IL-1β, NO) induced by AβO in primary mouse microglia, suppresses oxidative stress, and restores the antioxidant capacity of cells^[5].
Gamma-glutamylcysteine ammonium (0.25-2 mM; 12 h) increases GSH levels, GSH/GSSG ratio, GPX activity, and cell viability in primary cortical neurons treated with OGD/R, with the strongest effect observed at 2 mM for 12 h^[6].
Gamma-glutamylcysteine ammonium (0.85-7 mM; 12 h) increases GSH level, GSH/GSSG ratio, GPX activity and cell viability in PC12 cells treated with oxygen-glucose deprivation/reoxygenation (OGD/R)^[6].
Gamma-glutamylcysteine ammonium (1.7-7 mM; 0-12 h, time-course 0-12 h) regulates the mRNA and protein levels of GSS in OGD/R-treated PC12 cells, promotes nuclear translocation of Nrf2 in cells, reduces the interaction between Nrf2 and Keap1, inhibits the upregulation of Keap1, decreases MDA and Fe²⁺levels, improves cell viability, and thereby inhibits ferroptosis in cells^[6].
Gamma-glutamylcysteine ammonium (3.5 mM; 12 h, time-course 0-12 h) activates Nrf2 in OGD/R-treated PC12 cells by increasing the level of phosphorylated PKC-ε^[6].
Gamma-glutamylcysteine ammonium (200 μM; 15 min pre-incubation, 24 h co-incubation with oligomeric Aβ₄₀) protects primary human astrocytes against oligomeric Aβ₄₀-induced cytotoxicity, apoptosis, oxidative stress, neuroinflammation, and dysregulated metalloproteinase activity, while restoring antioxidant status and GSH levels^[7].
Gamma-glutamylcysteine ammonium (20-80 μM; 2 h pretreatment followed by 24 h ethanol exposure; 400 μM; 24 h single treatment) protects human L02 hepatocytes against ethanol-induced injury by dose-dependently increasing cell viability, reducing hepatic enzyme release, inhibiting cell apoptosis, suppressing oxidative stress and mitochondrial damage, and attenuating the activation of pro-inflammatory signaling pathways^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

insulin + palmitic acid-induced insulin-resistant HepG2 cells, primary mouse hepatocytes, C2C12 mouse skeletal muscle myotubes
Concentration:

0, 20, 40, 80 μM
Incubation Time:

24 h (following 24 h insulin + PA pre-treatment)
Result:

Significantly increased phosphorylation of p-IGF-1R (Tyr1135), p-IRS1 (Tyr612), p-PI3K, and p-Akt (Ser473) in a dose-dependent manner relative to insulin + PA-only treated cells across all three cell types, with significant increases observed at 20, 40, and 80 μM.

Apoptosis Analysis^[4]

Cell Line:

PC12 cells
Concentration:

4 mM
Incubation Time:

2 h pretreatment + 12 h cadmium exposure
Result:

Significantly reduced the number of TUNEL-positive PC12 cells.
Decreased the percentage of apoptotic cells induced by cadmium.

Western Blot Analysis^[4]

Cell Line:

PC12 cells
Concentration:

4 mM
Incubation Time:

2 h pretreatment + 12 h cadmium exposure
Result:

Down-regulated the ratio of Bax/Bcl-2 in cadmium-treated PC12 cells.
Reduced the protein levels of cytosolic cytopigment c, cleaved-caspase-9, cleaved-caspase-3, and cleaved-PARP in cadmium-treated PC12 cells.

In Vivo

Gamma-glutamylcysteine ammonium (600-1200 mg/kg; p.o.; daily; ~3 days) significantly increases the survival rate of mice with TNBS-induced inflammatory bowel disease, alleviates colon damage, and shifts macrophage polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, with both doses exhibiting therapeutic efficacy^[1].
Gamma-glutamylcysteine ammonium (250-500 mg/kg; p.o.; daily; 8 weeks) dose-dependently improves glycemic control, insulin sensitivity, β-cell function and hepatic steatosis, while alleviating diabetes-related organ damage in db/db mice^[3].
Gamma-glutamylcysteine ammonium (100-400 mg/kg/d; p.o.; daily; 20 days) dose-dependently inhibits AβO-induced neuroinflammation in male ICR mice^[5].
Gamma-glutamylcysteine ammonium (688 mg/kg; p.o.; single dose) upregulates GSH by activating the PKC-ε/Nrf2/GSS pathway, and significantly reduces cerebral infarction volume, neurological dysfunction, and neuronal ferroptosis induced by cerebral ischemia/reperfusion injury in male Sprague-Dawley rats^[6].
Gamma-glutamylcysteine ammonium (600 mg/kg; p.o.; once) significantly reduces the level of ds-HMGB1 in DRG of OIPN mice and reverses oxaliplatin-induced mechanical hyperalgesia^[8].
Gamma-glutamylcysteine ammonium (700-1200 mg/kg; p.o.; daily; 7 days) alleviates acute ethanol-induced hepatotoxicity in male C57BL/6JNifdc mice in a dose-dependent manner by reducing hepatic enzyme release, restoring hepatic antioxidant levels, alleviating histopathological damage, and inhibiting inflammatory signaling pathways^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (8-week-old male, 20-22 g, TNBS-induced colitis)^[1]
Dosage:

600 mg/kg; 1200 mg/kg
Administration:

p.o.; daily; ~3 days
Result:

Conferred significant protection against lethality.
Reversed TNBS-induced body weight loss.
Reduced the increase in Disease Activity Index (DAI).
Mitigated colon shortening, bleeding, and ulcerations.
Lowered histological injury scores.
Significantly reduced colon tissue mRNA levels of M1 markers (Inos, Il-1β).
Significantly increased colon tissue mRNA levels of M2 markers (Cd206, Arg1).
Significantly reduced serum TNF-α levels relative to the TNBS model group.
Confirmed reduced M1 marker (iNOS, IL-1β) and increased M2 marker (CD206, ARG1) protein levels in colon tissue via Western blot and immunohistochemistry.
Significantly reduced TNBS-induced phosphorylation of JAK1, STAT1, STAT3, AKT, JNK, ERK, p38, IKKα/β, and IkBα in colon lamina propria mononuclear cells.
Increased phosphorylation of STAT6 and serum IL-4 levels.

Animal Model:

C57BL/6J mice (male, 6 weeks old, 20-22 g); db/db mice (male, 6 weeks old, 30-35 g, spontaneous leptin receptor mutation model)^[3]
Dosage:

250 mg/kg; 500 mg/kg
Administration:

p.o.; daily; 8 weeks
Result:

Significantly decreased food intake, food efficiency, and water intake in db/db mice at 500 mg/kg dose.
Decreased water intake in db/db mice at 250 mg/kg dose.
Dose-dependently decreased fasting blood glucose, serum HbA1c, serum insulin levels, and HOMA-IR index, while increased HOMA-β index in db/db mice.
Dose-dependently improved glucose tolerance (reduced oral glucose tolerance test AUC) and insulin sensitivity (reduced insulin tolerance test AUC) in db/db mice.
Dose-dependently improved organ coefficients (reduced liver coefficient, increased cardiac and kidney coefficients) and reduced tissue damage (cardiomyocyte degeneration, kidney glomerular/tubular damage, hepatocyte ballooning, pancreatic islet loss) in db/db mice, with 500 mg/kg treatment more effective than metformin.
Dose-dependently reduced urinary MAU/ALB levels and increased hepatic glycogen content in db/db mice.
Dose-dependently reduced subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) weight, and decreased adipocyte size in db/db mice.
Dose-dependently reduced hepatic triglyceride (TG), total cholesterol (TC), and serum TG, TC, LDL-C levels, while increased serum HDL-C levels in db/db mice; 500 mg/kg treatment reduced hepatic TG more effectively than metformin.
Dose-dependently reduced hepatic lipid droplet accumulation (Oil Red O staining) and decreased serum ALT and AST levels in db/db mice.
Dose-dependently reduced hepatic CD36, PPARα, and CPT1A protein expression, and increased hepatic p-IGF-1R, p-IRS1, p-PI3K, and p-Akt protein expression in db/db mice.
Showed no significant effect on body weight, fasting blood glucose, organ coefficients, or tissue histology in C57BL/6J mice at both doses.

Animal Model:

ICR mice (male, 22-25 g, Alzheimer's disease model induced by intracerebroventricular administration of 2 μg AβO)^[5]
Dosage:

100 mg/kg/d; 400 mg/kg/d
Administration:

p.o.; daily; 20 days
Result:

Suppressed AβO-induced microglial activation (reduced Iba1 fluorescence intensity in the hippocampus), and inhibited upregulation of hippocampal COX-2, iNOS, and Iba1 protein expression (100 mg/kg/d dose).
Suppressed AβO-induced microglial activation with greater reduction in Iba1 fluorescence intensity than the 100 mg/kg/d dose, and exhibited stronger inhibition of AβO-induced upregulation of hippocampal COX-2, iNOS, and Iba1 protein expression compared to the 100 mg/kg/d dose (400 mg/kg/d dose).

Animal Model:

Sprague-Dawley (SD) (male, 260-300 g, transient focal cerebral ischemia induced by 90-minute middle cerebral artery occlusion followed by reperfusion)^[6]
Dosage:

688 mg/kg
Administration:

p.o.; single dose (administered 1.5 hours after MCAO)
Result:

Significantly reduced cerebral infarction volume.
Significantly lowered neurological deficit scores.
Significantly increased the number of Nissl-positive neurons in the ipsilateral cerebral cortex.
Significantly reduced the number of FJB+/NeuN+ (dying) neurons in the cerebral cortex.
Alleviated MCAO/R-induced neuronal mitochondrial damage, including reduced loss of mitochondrial cristae and outer membrane rupture.
Significantly decreased cortical H₂O₂, malondialdehyde (MDA), and Fe²⁺ levels, and reduced 4-HNE-positive neuronal counts.
Restored MCAO/R-induced alterations in ferroptosis-related protein and mRNA levels: increased FTH1 and GPX4, and decreased ACSL4 and TF (no effect on SLC7A11).
Significantly elevated cortical GSH levels, GSH/GSSG ratio, and glutathione peroxidase (GPX) activity.
Inhibited MCAO/R-induced reduction of cortical GSS mRNA and protein levels, and increased GSS/NeuN-positive neuron counts.
Increased total Nrf2 and phosphorylated Nrf2 protein levels in cortical tissue, and elevated Nrf2/NeuN and p-Nrf2/NeuN-positive neuron counts.
Increased phosphorylated PKC protein levels in cerebral cortical tissue.

Animal Model:

C57BL/6J (male, 8-10 weeks old, 22-26 g, SPF grade, oxaliplatin-induced peripheral neuropathy model)^[8]
Dosage:

600 mg/kg
Administration:

p.o.; 2 hours prior to each weekly oxaliplatin injection
Result:

Reduced ds-HMGB1 levels in the DRG to ~2.0 relative units.
Produced a smaller reduction in serum ds-HMGB1 to ~1.6 relative units.
Increased paw withdrawal thresholds to ~1.2 g, reversing oxaliplatin-induced mechanical allodynia.
Reduced cold escape behavior scores to ~4.0, modestly improving cold sensitivity.
Exhibited greater efficacy at reducing DRG ds-HMGB1 levels and improving pain responses than equimolar glutathione.

Animal Model:

C57BL/6JNifdc (male, 6-8 weeks old, acute ethanol-induced hepatotoxicity model)^[9]
Dosage:

700 mg/kg; 1200 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Reduced ethanol-induced elevations in serum ALT, AST, and TG levels in a dose-dependent manner.
Reversed ethanol-induced depletion of hepatic GSH levels.
Reduced hepatic lipid droplet formation and inflammatory cell infiltration.
Decreased ethanol-induced increases in hepatic protein levels of iNOS, p-p65, p-IKKα/β, and p-IκBα in a dose-dependent manner.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Molecular Weight 267.30
Formula C₈H₁₇N₃O₅S
SMILES

OC([C@H](CCC(N[C@H](C(O)=O)CS)=O)N)=O.N
Synonyms

γ-Glu-Cys ammonium
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (4)

All Bio/Physico-chemical AssayWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Rep

Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling. [Abstract]

2025 Dec 10;44(12):116671. PMID: 41385369

Gamma-glutamylcysteine ammonium purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Dec 10;44(12):116671. [Abstract]

Administration of glutathione (GSH) or Gamma-glutamylcysteine (γ-GC, a cell-permeable GSH analog) (600 mg/kg; p.o.; single dose) targeted to the DRG during OIPN. Western blots showing that oral γ-GC (which elevates intracellular GSH) significantly decreases DRG ds-HMGB1 compared to untreated OIPN controls (and more effectively than equimolar GSH).

Gamma-glutamylcysteine ammonium purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Dec 10;44(12):116671. [Abstract]

Behavioral assessments demonstrating that Gamma-glutamylcysteine (γ-GC, 600 mg/kg; p.o.; single dose) treatment mitigates pain: mechanical allodynia thresholds and cold-plate latencies/scores in OIPN mice at week 1. γ-GC reverses oxaliplatin-induced hypersensitivity, whereas GSH has a more modest effect.
Probiotics Antimicrob Proteins

Lactobacillus crispatus 7-4 Mitigates Salmonella typhimurium-Induced Enteritis via the γ‑Glutamylcysteine-Mediated Nrf2 Pathway. [Abstract]

2024 Jun 3. PMID: 38829566
Food Chem (Oxf)

Glutathione as a taste modulator: molecular mechanisms of interaction with umami and sweet taste receptors. [Abstract]

2025 Oct 26:11:100319. PMID: 41246561

Gamma-glutamylcysteine ammonium purchased from MedChemExpress. Usage Cited in: Food Chem (Oxf). 2025 Oct 26:11:100319. [Abstract]

Dose-response curves of hTAS1R1/rTAS1R3 stimulated with GSH, Gamma-glutamylcysteine (Glu-Cys), and GSSG. The results showed that the application of Glu-Cys produced weak agonist activity, with an EC₅₀ value of 3204 ± 1543 μM and a max ∆F/F0 of 0.42 ± 0.07.
Structure

Structural insights into the convergent evolution of sulfoxide synthase EgtB-IV, an ergothioneine-biosynthetic homolog of ovothiol synthase OvoA. [Abstract]

2024 Nov 7;32(11):2013-2022.e5. PMID: 39216472

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (297 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhou J, et al. γ-Glutamylcysteine rescues mice from TNBS-driven inflammatory bowel disease through regulating macrophages polarization. Inflamm Res. 2023 Mar;72(3):603-621. [Content Brief]

[2]. Wu H, et al. Lactobacillus crispatus 7-4 Mitigates Salmonella typhimurium-Induced Enteritis via the γ‑Glutamylcysteine-Mediated Nrf2 Pathway. Probiotics Antimicrob Proteins. 2025;17(5):3378-3391. [Content Brief]

[3]. Zhou J, et al. γ-glutamylcysteine alleviates insulin resistance and hepatic steatosis by regulating adenylate cyclase and IGF-1R/IRS1/PI3K/Akt signaling pathways. J Nutr Biochem. 2023 Sep;119:109404. [Content Brief]

[4]. Bi A, et al. γ-glutamylcysteine suppresses cadmium-induced apoptosis in PC12 cells via regulating oxidative stress. Toxicology. 2022;465:153029. [Content Brief]

[5]. Bi A, et al. γ-Glutamylcysteine attenuates amyloid-β oligomers-induced neuroinflammation in microglia via blocking NF-κB signaling pathway. Chem Biol Interact. 2022;363:110019. [Content Brief]

[6]. Zhang R, et al. γ-Glutamylcysteine Exerts Neuroprotection Effects against Cerebral Ischemia/Reperfusion Injury through Inhibiting Lipid Peroxidation and Ferroptosis. Antioxidants (Basel). 2022;11(9):1653. Published 2022 Aug 25. [Content Brief]

[7]. Braidy N, et al. The Precursor to Glutathione (GSH), γ-Glutamylcysteine (GGC), Can Ameliorate Oxidative Damage and Neuroinflammation Induced by Aβ₄₀ Oligomers in Human Astrocytes. Front Aging Neurosci. 2019;11:177. Published 2019 Aug 8. [Content Brief]

[8]. Yang Y, et al. Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling. Cell Rep. 2025;44(12):116671. [Content Brief]

[9]. Liu J, et al. γ-Glutamylcysteine alleviates ethanol-induced hepatotoxicity via suppressing oxidative stress, apoptosis, and inflammation. J Food Biochem. 2022;46(10):e14318. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Gamma-glutamylcysteine ammonium

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Gamma-glutamylcysteine ammonium

Publications Citing Use of MedChemExpress (MCE) Gamma-glutamylcysteine ammonium

All Interleukin Related Isoforms

All TNF Receptor Isoforms

All Endogenous Metabolite Isoforms

All AMPK Isoforms

All Sirtuin Isoforms

All STAT Isoforms

All PI3K Isoforms

All NF-κB Isoforms

All JAK Isoforms

All p38 MAPK Isoforms

All JNK Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (4)

Purity & Documentation

References

Calculators

Help & FAQs

Gamma-glutamylcysteine ammonium Related Classifications

HY-113402B Related Classifications

Bioz